HCHS/SOL is a study of 16 415 Hispanic/Latino adults recruited from 4 US communities (Bronx, Miami, Chicago, and San Diego) [5, 6] . Participants completed physical examinations, in-person interviews, and provided blood samples. Interviews did not include questions related to drug use or sexual behaviors.
Prevalence of hepatitis C virus (HCV) antibody in US populations, such as non-Hispanic/non-Latino Whites, non-Hispanic/ non-Latino Blacks, and persons of Mexican background, is commonly estimated using data from the National Health and Nutrition Examination Surveys (NHANES) [1] [2] [3] . NHANES include substantial numbers of Mexican background participants but relatively small numbers of Hispanic/Latino participants from other backgrounds. Whether HCV antibody prevalence differs between US Hispanic/Latino groups of different backgrounds is therefore not well understood.
During 2008-2011 Hispanic/Latino adults from 4 US communities (Bronx, Miami, Chicago, and San Diego) were recruited to participate in the Hispanic Community Health Study/ Study of Latinos (HCHS/SOL). In addition to Hispanic/Latino background, HCHS/SOL interviews assessed many of the same characteristics as NHANES. In this study we present data from NHANES 2007-2010 and HCHS/SOL side by side to provide a current picture of HCV antibody prevalence and correlates of HCV infection in US Hispanics/Latinos.
MATERIALS AND METHODS

Study Populations
NHANES are nationally representative samples of the noninstitutionalized US population conducted by the National Center for Health Statistics (NCHS). NHANES 2007-2010 participants completed in-person interviews that assessed demographics and many aspects of health and behavior; those over the age of 19 also provided information on drug use and sexual behaviors. NHANES 2007-2010 oversampled individuals of all Hispanic/Latino backgrounds, but only Hispanics/Latinos of Mexican background were enrolled in sufficient numbers to permit separate analyses of this group [4] . Hispanic/Latino NHANES participants who were not of Mexican background were classified as "Other Hispanic." NHANES protocols were approved by the NCHS Research Ethics Review Board, and all participants provided informed consent. NHANES 2007-2010 included 20 686 participants of whom 6875 were Hispanic/Latino. Because HCHS/SOL recruited individuals 18-74 years of age, we excluded 3388 NHANES 2007-2010 Hispanics/Latinos with ages outside this range. Also excluded were 277 participants without HCV antibody data.
HCHS/SOL is a study of 16 415 Hispanic/Latino adults recruited from 4 US communities (Bronx, Miami, Chicago, and San Diego) [5, 6] . Participants completed physical examinations, in-person interviews, and provided blood samples. Interviews did not include questions related to drug use or sexual behaviors.
The HCHS/SOL protocol was approved by each local institutional review board, and all participants provided informed consent. In total, 2694 participants recruited early in the study were not asked to provide consent for HCV testing and were not tested for HCV. A further 1502 participants were not tested for HCV because consent for HCV testing was not provided in time for inclusion in the testing panel. Also excluded were 213 participants who refused consent, 6 participants older than 74 years of age, 11 participants whose HCV testing had not been completed, and 25 participants with indeterminate HCV antibody results.
We compared 11 964 HCHS/SOL participants included in the analysis to those who were excluded. There were no differences by age and sex (both P ≥ .05). However, there were differences by geographic region and Hispanic/Latino background (both P < .01), which reflect the timeline by which consent for HCV testing was introduced into the 4 recruitment sites. Specifically, included participants were more likely to be of Cuban background and less likely to be of Puerto Rican background than those excluded.
Laboratory Methods
The VITROS Anti-HCV assay (Ortho Clinical Diagnostics, Raritan, NJ) was used to test NHANES samples for antibody directed against HCV. Positive samples were repeated in duplicate, and repeatedly positive samples were confirmed using the CHIRON RIBA HCV 3.0 SIA assay (Bio-Rad Laboratories, Hercules, CA). HCV antibody-positive samples were tested for HCV RNA using the COBAS AMPLICOR HCV Test, v2.0 (Roche Molecular Diagnostics, Pleasanton, CA).
The ADVIA Centaur HCV immunoassay (Siemens Diagnostics, Deerfield, IL) was used to perform HCV antibody testing in HCHS/SOL. If the HCV immunoassay was positive, the Abbott RealTime HCV assay (Abbott Molecular, Des Plaines, IL) was used to test for HCV RNA. If the HCV RNA test result was negative, the sample was retested with the CHIRON RIBA HCV 3.0 SIA assay (Bio-Rad Laboratories, Hercules, CA) to confirm the result of the immunoassay.
Statistical Methods
Prevalence estimates of HCV antibody overall and within strata of interest were calculated using sampling weights provided by NHANES 2007-2010 and HCHS/SOL. To enable comparison of prevalence estimates from the two studies, we age-standardized the weighted prevalence estimates by the direct method using data from the US 2010 Census. To facilitate interpretation, throughout the article we refer to age-standardized weighted prevalence of HCV antibody as "HCV prevalence." Survey-weighted χ 2 tests were used to assess differences in HCV prevalence between strata. Prevalences of HCV in NHANES 2007-2010 and HCHS/SOL were compared by calculating a standardized rate ratio and its 95% confidence interval (CI). Survey-weighted logistic regression was used to assess whether demographic and behavioral characteristics had independent associations with HCV prevalence. Prevalence of HCV RNA is reported among those positive for HCV antibody with nonmissing HCV RNA data.
RESULTS
Characteristics of the Study Populations
Fifty-two percent of the 3210 NHANES 2007-2010 Hispanics/ Latinos were male, and the median age was 36. The majority (63%) were born outside the 50 US states, 63% were of Mexican background, and 23% had incomes <$20 000. Forty percent of the 11 964 HCHS/SOL participants were male, and the median age was 47. The majority (83%) were born outside the 50 US states, and 47% had incomes <$20 000. HCHS/SOL included Hispanics/Latinos of multiple backgrounds: Mexican (39%), Cuban (16%), Puerto Rican (15%), Dominican (9%), Central American (11%), South American (7%), and mixed/other Hispanic/Latino (3%). Supplementary Tables 1 and 2 show HCV prevalence for men and women, respectively, by characteristics assessed in both NHANES 2007-2010 and HCHS/SOL. In HCHS/SOL, HCV prevalence was highest in Puerto Rican background participants (vs Mexican background participants, P < .01 for both men and women) and lowest in South American background participants (vs Mexican background participants, P < .05 for both men and women). In NHANES 2007-2010, there was no significant difference in HCV prevalence between Mexican background participants and those of "Other Hispanic" background.
Prevalence of HCV by Demographic and Behavioral
In logistic regression analyses that included all demographic and behavioral characteristics as covariates, associations between Puerto Rican and South American backgrounds and HCV prevalence remained statistically significant in HCHS/ SOL men, whereas South American background remained significant and Puerto Rican background was borderline significant (P = .05) in HCHS/SOL women (Table 1) . Other Table 1 
Prevalence of HCV by High-Risk Behaviors: NHANES 2007-2010
HCV prevalence was significantly higher in individuals who reported (i) using marijuana or hashish, (ii) using cocaine, heroin or methamphetamine, (iii) having first sex at younger than 18 years, and (iv) having >10 sexual partners vs <5 partners in univariable analyses. In logistic regression analyses that included adjustment for the characteristics shown in Supplementary Tables 1  and 2 , the association with cocaine, heroin, or methamphetamine use remained statistically significant (data not shown).
Prevalence of HCV by Recruitment Site and Hispanic/Latino Background Group: HCHS/SOL
Participants in the Bronx had an HCV prevalence of 4.5%, significantly higher than those in San Diego (1.7%), Chicago (1.2%), and Miami (0.8%; P < .01 for the Bronx compared to other sites). As shown in Figure 1 , men and women of Puerto Rican background in the Bronx had the highest HCV prevalence (14.2% and 4.1%, respectively). In comparison, HCV prevalences among men and women of Puerto Rican background in Chicago were 4.7% and 1.3%, respectively. Tables 1 and  2 ). These data signify that the scale of the HCV epidemic varies between Hispanic/Latino background groups. Many of the same associations with HCV prevalence were observed in NHANES 2007-2010 and HCHS/SOL. For example, English language interview, birth in the 50 US states, and cigarette smoking were associated with significantly higher HCV prevalence in men and women in both studies. However, in multivariable analyses of HCHS/SOL that included Hispanic/Latino background, associations between interview language, nativity, and HCV prevalence became nonsignificant. In contrast, interview language retained a significant association and nativity had a marginal (P = .05) association with HCV prevalence in multivariable analysis of NHANES men. Together, these data suggest that differences in HCV prevalence by language and nativity may actually reflect differences between Hispanic/Latino background groups. HCV prevalence was high among Puerto Rican background participants in HCHS/SOL, and it is possible that some of their HCV infections were acquired in Puerto Rico. For example, in 2001-2002, a population-based survey of adults in San Juan, Puerto Rico, found that 10.6% of the male population was HCV-seropositive and that 6.2% of adults (both men and women) reported prior heroin use [7] . Alternatively, it could be that participants of Puerto Rican background were primarily at risk for HCV infection in the 50 US states, particularly in the Bronx. A recent study of 9579 patients receiving care at Bronx primary care clinics estimated HCV prevalence to be 4.6%-7.7% [8] . These patients were predominantly women (72%) and minority (51% Hispanic/Latino, 32% non-Hispanic/nonLatino Black), with a mean age of 49 years [8] . In subgroup analysis of this population, HCV prevalence was 14.8% among 1334 Hispanic/Latino men and 5.5% among 3581 Hispanic/ Latino women (William Southern, personal communication). A similar study of 1000 primary care patients in a neighborhood adjacent to the Bronx found that 8.3% were HCV seropositive [9] .
There are several limitations that must be considered. First, the proportion of eligible individuals who agreed to participate was 41.7% in HCHS/SOL and 75.4% and 77.3% in NHANES 2007-2008 and NHANES 2009-2010, respectively. Although both studies were weighted for nonresponse, it is possible that individuals who declined to participate differed from those who did participate, and that these differences were not controlled through weighting procedures. Second, HCHS/SOL is not representative of all US Hispanics/Latinos, and studies of Hispanic/Latino populations in other areas could yield different results. Indeed, the findings suggest that prevalence estimates of HCV antibody in US Hispanics/Latinos depend on the specific populations studied. For example, had more Puerto Rican background participants been included in the HCHS/SOL testing panel, the estimated prevalence of HCV antibody in HCHS/ SOL might have been higher.
Overall, this study shows that the HCV epidemic among US Hispanic/Latino adults is heterogeneous. This information will be useful to those who direct public health resources for HCV treatment and prevention. Clinicians who serve Hispanic/ Latino communities may also benefit from this information because it highlights specific Hispanic/Latino groups that may benefit from increased levels of HCV testing and treatment.
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